載入...

3′-Phosphoadenosine 5′-phosphosulfate synthase 1 (PAPSS1) knockdown sensitizes non-small cell lung cancer cells to DNA damaging agents

Standard treatment for advanced non-small cell lung cancer (NSCLC) with no known driver mutation is platinum-based chemotherapy, which has a response rate of only 30–33%. Through an siRNA screen, 3′-phosphoadenosine 5′-phosphosulfate (PAPS) synthase 1 (PAPSS1), an enzyme that synthesizes the biologi...

全面介紹

Na minha lista:
書目詳細資料
發表在:Oncotarget
Main Authors: Leung, Ada W. Y., Dragowska, Wieslawa H., Ricaurte, Daniel, Kwok, Brian, Mathew, Veena, Roosendaal, Jeroen, Ahluwalia, Amith, Warburton, Corinna, Laskin, Janessa J., Stirling, Peter C., Qadir, Mohammed A., Bally, Marcel B.
格式: Artigo
語言:Inglês
出版: Impact Journals LLC 2015
主題:
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4627299/
https://ncbi.nlm.nih.gov/pubmed/26220590
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!